# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

> **NCT03933488** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 121 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** TAK-994
- **DRUG:** TAK-994 Placebo

## Key facts

- **NCT ID:** NCT03933488
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2020-03-29
- **Final completion:** 2020-03-29
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2020-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03933488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03933488, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03933488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*